FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:68 January 4, 2001 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Bone marrow transplantation can eliminate sickle cell disease and halt end-organ damage.^1,2 However, the applicability of the procedure is limited because of the toxic effects associated with conventional bone marrow transplantation. Nonmyeloablative conditioning regimens can decrease or eliminate such toxic effects.^3,4,5

An eight-year-old girl with homozygous sickle cell disease had been receiving monthly transfusions and chelation therapy with deferoxamine since having a stroke three years earlier. Before the stroke, she had required three or four hospitalizations per year for vaso-occlusive crises and the acute chest syndrome. We treated the girl with a bone marrow transplant from her . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Pulsipher, M. A., Boucher, K. M., Wall, D., Frangoul, H., Duval, M., Goyal, R. K., Shaw, P. J., Haight, A. E., Grimley, M., Grupp, S. A., Kletzel, M., Kadota, R. (2009). Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 114: 1429-1436 [Abstract] [Full Text]  
• Perumbeti, A., Higashimoto, T., Urbinati, F., Franco, R., Meiselman, H. J., Witte, D., Malik, P. (2009). A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114: 1174-1185 [Abstract] [Full Text]  
• Kean, L. S., Durham, M. M., Adams, A. B., Hsu, L. L., Perry, J. R., Dillehay, D., Pearson, T. C., Waller, E. K., Larsen, C. P., Archer, D. R. (2002). A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 99: 1840-1849 [Abstract] [Full Text]  
• Walters, M. C., Nienhuis, A. W., Vichinsky, E. (2002). Novel Therapeutic Approaches in Sickle Cell Disease. ASH Education Book 2002: 10-34 [Abstract] [Full Text]  
• Suzan, F., Ammor, M., Ribrag, V. (2001). Fatal Reactivation of Cytomegalovirus Infection after Use of Rituximab for a Post-Transplantation Lymphoproliferative Disorder. NEJM 345: 1000-1000 [Full Text]  
• Bolan, C. D., Leitman, S. F., Griffith, L. M., Wesley, R. A., Procter, J. L., Stroncek, D. F., Barrett, A. J., Childs, R. W. (2001). Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 98: 1687-1694 [Abstract] [Full Text]  
• Zecca, M., De Stefano, P., Nobili, B., Locatelli, F. (2001). Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97: 3995-3997 [Abstract] [Full Text]